Natco Pharma marketing partner gets USFDA approval for Nitroglycerin Sublingual Tablets
Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart).
New Delhi: Drug firm Natco Pharma Wednesday said its marketing partner Alvogen has received final ANDA nod from USFDA for chest pain tablets.
"The company is pleased to announce that its marketing partner Alvogen has received the final approval of Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg," Natco Pharma said in a BSE filing.
Also Read: Natco Pharma submits new drug application with USFDA for generic Ibrutinib tablets
Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart), it said.
Pfizer Pharmaceuticals, the company said, markets this drug under its brand Nitrostat Sublingual Tablets in the same strengths mentioned above.
As per IQVIA data, Nitroglycerin Sublingual Tablets had total annual sales of around USD 77.3 million in the US market, for the year ending 2018, the company said.
Also Read: Natco Pharma shares decline nearly 5 percent after Q3 results
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd